AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteer

In brief

This is a Phase I randomized double-blind, placebo-controlled, single centre study to assess the safety, tolerability and pharmacokinetics of AZD7325 following single ascending dose administration to healthy male Japanese volunteers.

Key facts

Study ID

NCT00769899

Run by

AstraZeneca

People needed

48

Starts

2008-10-01

Expected to finish

2009-03-01

Last updated by the study team

2009-03-18

Who can join

Age: 20 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Body mass index (BMI) : 18 to 27 kg/m 2

You may not qualify if…

• Clinically relevant disease and/or abnormalities (past or present)
• Clinically relevant abnormalities in physical examinations,vital signs,clinical chemistry, hematology or urinalysis at screening as judged by the investigator
• Use of any medication or herbal preparation within 14 days of Study day 1 through the Follow-up Visit other than paracetamol (up to 3 g/day)
• Smoking in excess of 5 cigarettes per day or the equivalent within 28 days prior to the first study day or inability to refrain from smoking during the study confinement period

Where it is running

• Research Site — Glendale, California, United States
• Research Site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.